Otsuka

NEWS RELEASE

Otsuka Pharmaceutical Factory, Inc.
EN Otsuka Pharmaceutical Co., Ltd.
Otsuka Holdings Co., Ltd.

November 13, 2026

Otsuka Pharmaceutical Factory Launches ENOFEED® Liquid for Enteral Use

Otsuka Pharmaceutical Factory, Inc. (Head Office: Naruto, Tokushima; President and Representative Director: Shuichi Takagi; hereinafter "Otsuka Pharmaceutical Factory") announced that it will launch ENOFEED® Liquid for Enteral Use (hereinafter "ENOFEED"), an enteral formula, on December 4, 2026.

ENOFEED is an enteral formula for tube feeding with an energy density of 1.0 kcal/mL. It is formulated based on a daily energy intake of 900 kcal, taking into consideration the nutritional management of patients with low maintenance energy requirements.

Its energy-yielding nutrient balance was established based on the Dietary Reference Intakes for Japanese (2020), and the product contains iodine, selenium, chromium, and molybdenum. It also contains L-carnitine*1 and choline, taking into consideration the potential for deficiencies during long-term enteral nutritional management, as well as inulin*2 as a source of dietary fiber.

In addition, ENOFEED is supplied as a Ready to Hang (RTH) product that can be connected to a feeding set after opening without transferring the contents to another administration container.

Enteral formulas are widely used to provide nutritional support to postoperative patients and patients who have difficulty ingesting food orally over an extended period.

Older patients and patients with low levels of physical activity may be managed with relatively low maintenance energy intakes of approximately 1,000 kcal per day. In recent years, there has been a need in clinical settings for products designed with consideration for the nutritional management of patients with low maintenance energy requirements.

In response to these needs, ENOFEED has been formulated so that an intake of 900 kcal approximately meets the recommended dietary allowances or adequate intakes of vitamins and trace elements. We expect ENOFEED to serve as a new option for the nutritional management of patients with low maintenance energy requirements in clinical settings.

Otsuka Pharmaceutical Factory will continue to provide products and information that contribute to appropriate nutritional management, with the aim of becoming the best partner for patients and healthcare professionals in the field of clinical nutrition.

Under its corporate philosophy, "Otsuka-people creating new products for better health worldwide," the Otsuka group remains committed to contributing to the health of people around the world.

*1 L-carnitine: A micronutrient that plays an important role in energy production from lipids.
*2 Inulin: A water-soluble dietary fiber found in foods such as burdock root and onions. It is used in a variety of foods as a sweetener and food additive.

Product Information

Brand Name	ENOFEED® Liquid for Enteral Use
Regulatory Classification	None
Indications	Generally, this drug can be used to maintain nutritional status in postoperative patients; in particular, it is intended for nutritional support by tube feeding in patients with difficulty ingesting food orally over the long term.
Dosage and Administration	The standard adult dosage is 900-1,500 mL (900-1,500 kcal) per day, administered by tube feeding. The administration rate should be 50-400 mL/hour, and the daily amount should be administered continuously or in several divided doses. Patients should be carefully observed when the product is administered for the first time. The dosage should be gradually increased, with close attention paid to clinical symptoms, so that the standard dosage is reached within several days. The dosage and administration rate should be adjusted as appropriate according to the patient's age, body weight, symptoms, and nutritional status.
Packaging	 15 bags [1 bag (300 mL) × 15]
Storage	Store at room temperature
Shelf Life	13 months
NHI Drug Price	14.30 yen/10 mL (429 yen/300 mL bag)
Manufactured and Distributed by	EN Otsuka Pharmaceutical Co., Ltd.
Comarketed by	Otsuka Pharmaceutical Factory, Inc. Otsuka Pharmaceutical Co., Ltd.

Corporate Profile

Otsuka Pharmaceutical Factory, Inc.

Incorporated	:	October 7, 1969 (founded September 1, 1921)
Capital	:	40.08 billion yen
Representative	:	Shuichi Takagi, President and Representative Director
Head Office	:	115 Kuguhara, Tateiwa, Muya-cho, Naruto, Tokushima 772-8601, Japan
Employees	:	2,432 (as of December 31, 2025)
Business Description	:	Manufacture, sale, import and export of clinical nutrition products and other pharmaceutical products, medical devices, functional foods, etc.
URL	:	https://www.otsukakj.jp/en/